HC Wainwright & Co. Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target
HC Wainwright & Co. Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target
HC Wainwright公司重申對eyepoint pharmaceuticals的買入評級，維持30美元的目標價。
HC Wainwright & Co. analyst Yi Chen reiterates EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and maintains $30 price target.
HC韋恩萊特證券分析師陳怡重申買入 eyepoint pharmaceuticals，並維持30美元的目標價格。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。